Web15 set 2024 · This is the second licensing pact the Chinese-based pharma company has signed this summer. Back in May, Finland’s Orion penned a deal with Jemincare worth 15 million euros ($15.9 million) upfront for the rights to develop and sell the preclinical, non-opioid pain therapy JMKX000623 outside greater China. Previous Post Are SERDs dead? Web20 mag 2024 · Orion will be hoping to catch up, with plans to get JMKX000623 into the clinic later this year. If successful, Nanchang, China-based Jemincare will be on course for a “significant” but undisclosed haul of biobucks, Outi Vaarala, M.D., Ph.D., senior vice president of research and development at Orion, said in the May 6 announcement.
Orion Corp Lead Sheet - GlobalData
WebAfter penning a deal with Orion back in May, Jemincare is back at the licensing deal table, inking a development and sales deal with Roche’s Genentech unit that is on the lookout for a new ... Web12 mag 2024 · Orion Corp. has secured exclusive global rights, outside China, to a non-opioid pain drug candidate from Jiangxi Jemincare Group Co. Ltd. The deal, for oral … the productive agency in learning by teaching
Orion acquires rights to painkiller from China’s Jemincare
Web6 mag 2024 · Orion Corporation has entered into an agreement with Chinese Jemincare, through which Orion will receive exclusive global development and commersialisation … Web6 mag 2024 · ORION CORPORATION PRESS RELEASE 6 MAY 2024 at 9.00 EEST Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain Orion Corporation has entered into an agreement with Chinese Jemincare, through which Orion will receive exclusive global development and … WebNational Center for Biotechnology Information signal turn light